Lugano, Switzerland, 20 March 2025 – The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies. Renowned experts from around the globe will convene to present the latest research in the field, offering their insights on, among others, screening and early detection of thoracic tumours, molecular characterisation of lung cancer, advancements in immunology and targeted therapies, and the evolving role of multidisciplinary decision-making in lung cancer.
The event will take place in Paris between 26-29 March and will be live streamed on the Virtual Congress Platform.
Programme picks
- New results on the long-term anti-tumour activity of immunotherapy combined with chemotherapy in various non-small cell lung cancer settings.
- Novel data on the efficacy of subcutaneous over intravenous immunotherapies in treating NSCLC, emphasizing the benefits for both patients and healthcare professionals.
- Findings to extend treatment in EGFR-mutant advanced non-small cell lung cancer: from chemo-sparing strategies after disease progression to reducing adverse events in combination treatments.
- Insights on availability of and accessibility to molecular testing in Europe and beyond, and on how to optimise testing to address the issue of lung cancer patients being treated without biomarker results.
- New therapeutic strategies for non-small cell lung cancer with specific genetic mutations after first line of treatment and advancements in actionable genomic alterations.
- Insights on the role of AI in lung cancer imaging, response assessment, radiation treatment planning and computational pathology
Award lecture
-
“HHH: History, Histopathology & Hyperbole. Lung cancer pathology comes of age” by Keith Kerr, recipient of the Heine H. Hansen Award, 26 March 2025, 13:50-14:30 CET
Keynote lecture
-
“Less is more: De-escalation strategies in patient management and clinical trials” by Benjamin Besse, Fri, 28 March 2025, 14:00-14:30 CET
The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
Press representatives working for recognised outlets interested in obtaining information and reporting on cancer issues are welcome to report on ELCC upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ELCC 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: European Lung Cancer Congress 2025 or ELCC 2025 and the official congress hashtag #ELCC25. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube.
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from 179 countries and territories, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
About the International Association for the Study of Lung Cancer (IASCL)
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries. By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities. www.iaslc.org